Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
CAR-T Immunotherapy Targeting CD19- ALL
2027. júl. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Universal CAR-T Cells Targeting AML
2027. jún. 30.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Universal CAR-T Cells Targeting Multiple Myeloma
2027. jún. 30.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
2027. jún. 1.· PHASE1 · WITHDRAWN· CTGOV
Vizsgálat
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
2026. dec. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
2026. dec. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.
2026. nov. 1.· Radiology· PUBMED
Vizsgálat
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
2026. okt. 22.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publikáció
Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence.
2026. okt. 15.· Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association· PUBMED
Publikáció
CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.
2026. okt. 14.· Frontiers in medicine· PUBMED
Vizsgálat
FT839 in Autoimmune Diseases
2026. okt. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
2026. okt. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Synthesis, Evaluation, and Effect of Anti-CD38 Single-chain Immunotoxin on HL-60 acute myeloid Leukemia cell Line.
2026. szept. 29.· Current research in translational medicine· PUBMED
Publikáció
Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma.
2026. szept. 24.· Frontiers in immunology· PUBMED
Publikáció
Histone H3K18 Lactylation Drives Immunosuppression by Upregulating CD38 in Myeloid-Derived Suppressor Cells in Lung Cancer.
2026. szept. 18.· Cancer immunology research· PUBMED
Publikáció
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
2026. szept. 14.· Leukemia· PUBMED
Publikáció
Implementation of soluble CD38 in blood crossmatching for patients on anti-CD38 therapy: A single-center experience.
2026. szept. 11.· Transfusion· PUBMED
Vizsgálat
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
2026. szept. 10.· PHASE2 · RECRUITING· CTGOV
Publikáció
Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.
2026. szept. 2.· Blood· PUBMED
Vizsgálat
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
2026. szept. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Study of CD38 and CD56 in Chronic Myeloid Leukemia
2026. szept. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
2026. szept. 1.· Frontiers in immunology· PUBMED
Publikáció
Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study.
2026. aug. 27.· The Journal of international medical research· PUBMED
Publikáció
Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.
2026. aug. 25.· Therapeutic advances in hematology· PUBMED
Publikáció
mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.
2026. aug. 24.· Theranostics· PUBMED
Publikáció
Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.
2026. aug. 18.· BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy· PUBMED
Publikáció
CD38+ T-Cell Count Is an Immunologic Phenotype Associated With Blood Pressure.
2026. aug. 17.· Hypertension (Dallas, Tex. : 1979)· PUBMED
Vizsgálat
A Open-Label Phase in Participants With Multiple Myeloma
2026. aug. 15.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3.
2026. aug. 15.· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publikáció
Gut Microbiome Composition Is Associated With Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients.
2026. aug. 10.· Clinical lymphoma, myeloma & leukemia· PUBMED